These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Furan H2-antagonist ranitidine inhibits pentagastrin-stimulated gastric secretion stronger than cimetidine.
    Author: Domschke W, Lux G, Domschke S.
    Journal: Gastroenterology; 1980 Dec; 79(6):1267-71. PubMed ID: 6108279.
    Abstract:
    In each of 7 healthy volunteers, the new furan H2-antagonist ranitidine (0.125, 0.25, 0.5, and 1.0 mg . kg-1 . hr-1) or the imidazole derivative cimetidine or normal saline were intravenously infused in the midhour of a 3-hr pentagastrin period (1.5 micrograms . kg-1 . hr-1 i.v.). With increasing doses of ranitidine, gastric acid secretion dropped dose dependently: 62, 78, 89, and 94%, respectively (P < 0.05 for all doses). A cimetidine dose of 0.82 mg . kg-1 . hr-1 (2.8 mumol . kg-1 . hr-1), equivalent to the highest ranitidine dose, led to a similar reduction of acid output (54%) as an eightfold smaller ranitidine dose. Apparently in human gastric mucosa, recognition of H2-receptors is not exclusively determined by the imidazole ring. Strong inhibitory efficacy of ranitidine was also reflected by the low calculated mean ID50 of 54 micrograms (0.15 mumol) . kg-1 . hr-1 and the IC50 of 36 ng/ml (0.1 microM). Acid inhibition by ranitidine involved both reduction in volume and acidity. The lowering effect on pepsin output was less pronounced though significant. Secretion of free N-acetylneuraminic acid and N-acetylneuraminic acid bound to glycoproteins did not change after H2-blocker administration indicating an unimpaired mucus secretion. In these short-term experiments, there were no obvious side effects or alterations in routine laboratory parameters including serum gastrin and prolactin attributable to either drug.
    [Abstract] [Full Text] [Related] [New Search]